1. Home
  2. INDI vs AKBA Comparison

INDI vs AKBA Comparison

Compare INDI & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INDI
  • AKBA
  • Stock Information
  • Founded
  • INDI 2007
  • AKBA 2007
  • Country
  • INDI United States
  • AKBA United States
  • Employees
  • INDI N/A
  • AKBA N/A
  • Industry
  • INDI Semiconductors
  • AKBA Biotechnology: Pharmaceutical Preparations
  • Sector
  • INDI Technology
  • AKBA Health Care
  • Exchange
  • INDI Nasdaq
  • AKBA Nasdaq
  • Market Cap
  • INDI 381.6M
  • AKBA 336.2M
  • IPO Year
  • INDI N/A
  • AKBA 2014
  • Fundamental
  • Price
  • INDI $1.91
  • AKBA $2.06
  • Analyst Decision
  • INDI Strong Buy
  • AKBA Strong Buy
  • Analyst Count
  • INDI 6
  • AKBA 3
  • Target Price
  • INDI $7.50
  • AKBA $6.50
  • AVG Volume (30 Days)
  • INDI 4.3M
  • AKBA 5.0M
  • Earning Date
  • INDI 05-12-2025
  • AKBA 05-08-2025
  • Dividend Yield
  • INDI N/A
  • AKBA N/A
  • EPS Growth
  • INDI N/A
  • AKBA N/A
  • EPS
  • INDI N/A
  • AKBA N/A
  • Revenue
  • INDI $216,682,000.00
  • AKBA $160,180,000.00
  • Revenue This Year
  • INDI $25.74
  • AKBA $22.50
  • Revenue Next Year
  • INDI $48.74
  • AKBA $43.23
  • P/E Ratio
  • INDI N/A
  • AKBA N/A
  • Revenue Growth
  • INDI N/A
  • AKBA N/A
  • 52 Week Low
  • INDI $1.53
  • AKBA $0.80
  • 52 Week High
  • INDI $7.82
  • AKBA $2.89
  • Technical
  • Relative Strength Index (RSI)
  • INDI 41.79
  • AKBA 56.65
  • Support Level
  • INDI $1.78
  • AKBA $1.52
  • Resistance Level
  • INDI $2.16
  • AKBA $1.86
  • Average True Range (ATR)
  • INDI 0.23
  • AKBA 0.15
  • MACD
  • INDI 0.05
  • AKBA 0.02
  • Stochastic Oscillator
  • INDI 60.61
  • AKBA 88.52

About INDI indie Semiconductor Inc.

Indie Semiconductor Inc is empowering the Autotech revolution with next-generation automotive semiconductors and software platforms. It focuses on edge sensors for advanced Driver Assistance Systems including LiDAR, connected car, user experience, and electrification applications. These technologies represent the core underpinnings of both electric and autonomous vehicles, while the advanced user interfaces transform the in-cabin experience to mirror and seamlessly connect to the mobile platforms. Geographically, the company generates majority of its revenue from Greater China and rest from United States, Europe, South Korea and other regions.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: